天天基金网·2025-09-04 05:09Core Viewpoint - FTSE Russell announced quarterly review changes for multiple indices, effective after the close on September 19, 2025, with significant implications for the FTSE China A50 Index [2][5]. Group 1: Index Changes - The FTSE China A50 Index will include stocks such as BeiGene-U, NewEase, WuXi AppTec, and Zhongji Xuchuang, which are primarily from the pharmaceutical and AI computing sectors [3][6]. - Stocks removed from the FTSE China A50 Index include China Nuclear Power, China Unicom, Guodian Nari, and Wanhua Chemical [6][7]. - The FTSE China A50 Index consists of the 50 largest stocks listed on the Shanghai and Shenzhen exchanges, reviewed quarterly [7]. Group 2: Stock Performance - BeiGene-U has doubled in value this year, with a growth rate of 102.51%, and a market capitalization of approximately 466.4 billion [7]. - WuXi AppTec also experienced a doubling in its stock price, while NewEase surged over three times, and Zhongji Xuchuang increased by over 240%, with a market cap exceeding 470 billion [7]. Group 3: Market Trends - The inclusion of stocks in the FTSE Russell indices often leads to significant buying pressure from index-tracking funds, particularly around the effective date of the changes [8]. - The AI computing sector is expected to see explosive growth in demand as it plays a crucial role in the AI industry, impacting various segments of the supply chain [11]. - The pharmaceutical sector is experiencing a shift towards innovation-driven growth, with a focus on value creation through new drug models, which is anticipated to result in greater market capitalization increases compared to previous cycles [11].